PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026Open Forum Infectious Diseases0 citationsOpen Access

P-143. Oral Vancomycin Prophylaxis to Control an Outbreak of Clostridium difficile Infection in ICU Patients in a Large Urban Safety Net Hospital

View Full Paper
AKAnjali KewalramaniSSShaurya SharmaKSKatrina Sandejas

Key Points

  • Evaluate the effectiveness of oral vancomycin prophylaxis in controlling HO-CDI in ICU patients.
  • Initiated prophylaxis for patients ≥ 60 years, hospitalized for ≥ 7 days, receiving specific antibiotics.
  • Compared HO-CDI rates during Outbreak, Prophylaxis, and Follow-up Periods in ICUs.
  • Monitored vancomycin-resistant enterococci rates during the same periods.
  • HO-CDI cases in ICUs decreased from 1.91 to 0.38 cases/1000 patient-days during the Prophylaxis Period (P=.02).
  • This reduction was maintained at 0.66 cases/1000 patient-days during the Follow-up Period (P=.06).
  • Rates of VRE cases remained stable across the three periods.

Abstract

Abstract Background Hospital-onset Clostridioides difficile infection (HO-CDI) is associated with significant clinical and economic consequences. Use of broad-spectrum antibiotics for patients in the Intensive Care Units (ICUs) is the leading risk for HO-CDI. Hospital outbreaks may still develop despite comprehensive antimicrobial stewardship programs and infection control measures. Methods In response to a large tertiary care urban hospital CDI outbreak in the adult medical and surgical ICUs, a program of primary oral vancomycin prophylaxis (OVP) for select high-risk patients was initiated. Primary prophylaxis was administered for patients ≥ 60 years of age, hospitalized for ≥ 7 days, and receiving a beta-lactam, fluoroquinolone, and/or clindamycin. The Outbreak Period was from Oct 1, 2023 through Mar 15, 2024. The Prophylaxis Period started Mar 16, 2024 and terminated on Aug 31, 2024; a Follow-up Period then was from Sep 1, 2024 to Feb 28, 2025. Patients outside the ICUs were not administered OVP. The number of cases of incident HO-CDI and vancomycin-resistant enterococci (VRE) cases were gathered; rates of infection were determined using the number of patient-days for the ICUs and for the remainder of the hospital during each time period. Results In the ICUs during the Outbreak Period, there were 1.91 HO-CDI cases/1000 patient-days. During the Prophylaxis Period, this fell to 0.38 cases/1000 patient days (P=.02). This decrease in HO-CDI cases in the ICUs was sustained during the 6-month Follow-up Period (0.66 cases/1000 patient days, P=.06 compared to Outbreak Period). For patients outside the ICUs, rates of HO-CDI remained unchanged during the three periods: 0.20, 0.29, and 0.13 cases/1000 patient days, P=NS). The rate of VRE cases in the ICUs remained stable during the three time periods: 0.70, 1.52, and 0.82 cases/1000 patient days (P=NS). Conclusion A restricted protocol of primary OVP helped terminate a sustained outbreak of HO-CDI in ICU patients; the favorable impact continued for 6 months after stopping primary OVP. OVP may be an effective option for preventing and controlling CDI in high-risk settings. Disclosures All Authors: No reported disclosures

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kewalramani et al. (2026) studied this question.

synapsesocial.com/papers/6966f33b13bf7a6f02c012e9https://doi.org/10.1093/ofid/ofaf695.370
Ask AI
Helpful
Bookmark
Share
View Full Paper